Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.

Terminal ileum resection is associated with increased risk for colorectal cancer among individuals with Crohn disease.

A four-strain probiotic blend has shown promise in easing IBS symptoms in IBD patients without active inflammation, offering ...